Diurnal, a portfolio company of AIM-listed Fusion IP, has raised £1.2 million of new capital as well as completing Phase I trails of its lead product Chronocort.
Pharmaceutical business Evgen, a developer of a drug that may prevent and treat prostate cancer and other cancer, has closed a Series A investment round led by The North West Fund for Biomedical.
Biotechnology company KalVista Pharmaceuticals has raised £8 million in a Series A financing round from life sciences venture investors Novo A/S and SV Life Sciences to develop a treatment for diabetes-related blindness.
Biopharmaceutical company Shire has acquired American business Advanced BioHealing as part of its move to build a new strategic business unit in regenerative medicine.
Pharmaceutical company Acacia Pharma, a developer of drugs for cancer care support, has raised $10 million (£6.2 million) in a Series A investment round.
